In patients randomized to the Allurion Program alone, weight loss was 13.7% at four months and resolution of type 2 diabetes, hypertension, and obstructive sleep apnea was observed in 55.5%, 58.8%, and 57.8%, respectively
Suzuki R, Brown GA, Christopher JA, et al
GLP-1 receptor agonists, such as semaglutide (Ozempic, Wegovy) and liraglutide (Saxenda, Victoza), have become prominent in the management of Type 2 diabetes and weight loss
The amount of weight lost is the main driver
Dazu gehrt auch eine unter anderem via Facebook verbreitete angebliche ZDF-Sendung von Markus Lanz mit Dr
The clinical consensus is that having no gallbladder is not a contraindication for taking semaglutide